Drug Trial Radar · NCT04252066
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 18, 2025
Primary completion
Aug 2029
Study completion Feb 2030
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.
Conditions
- Fabry Disease
Interventions
migalastatDrug
This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of major birth defectsTime frame: Through the pregnancy, an average of 40 weeks and up to 12 months of infant age
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amicus Therapeutics, Inc. Pregnancy Registry
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.